These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
561 related articles for article (PubMed ID: 37457713)
1. Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights. Ma Y; Du J; Chen M; Gao N; Wang S; Mi Z; Wei X; Zhao J Front Immunol; 2023; 14():1219652. PubMed ID: 37457713 [TBL] [Abstract][Full Text] [Related]
2. Exploring the role of sphingolipid-related genes in clinical outcomes of breast cancer. Pei S; Zhang P; Yang L; Kang Y; Chen H; Zhao S; Dai Y; Zheng M; Xia Y; Xie H Front Immunol; 2023; 14():1116839. PubMed ID: 36860848 [TBL] [Abstract][Full Text] [Related]
3. Integrating single-cell RNA-seq and bulk RNA-seq to construct prognostic signatures to explore the role of glutamine metabolism in breast cancer. Pei S; Zhang P; Chen H; Zhao S; Dai Y; Yang L; Kang Y; Zheng M; Xia Y; Xie H Front Endocrinol (Lausanne); 2023; 14():1135297. PubMed ID: 36843602 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model. Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787 [TBL] [Abstract][Full Text] [Related]
5. Oncogenic signaling pathway-related long non-coding RNAs for predicting prognosis and immunotherapy response in breast cancer. Li H; Liu H; Hao Q; Liu X; Yao Y; Cao M Front Immunol; 2022; 13():891175. PubMed ID: 35990668 [TBL] [Abstract][Full Text] [Related]
6. Development and validation a prognostic model based on natural killer T cells marker genes for predicting prognosis and characterizing immune status in glioblastoma through integrated analysis of single-cell and bulk RNA sequencing. Hu J; Xu L; Fu W; Sun Y; Wang N; Zhang J; Yang C; Zhang X; Zhou Y; Wang R; Zhang H; Mou R; Du X; Li X; Hu S; Xie R Funct Integr Genomics; 2023 Aug; 23(3):286. PubMed ID: 37650991 [TBL] [Abstract][Full Text] [Related]
7. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer. Wang Z; Liu H; Gong Y; Cheng Y Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948 [TBL] [Abstract][Full Text] [Related]
8. Comprehensive Xu T; Xu W; Zheng Y; Li X; Cai H; Xu Z; Zou Q; Yu B Front Immunol; 2022; 13():931906. PubMed ID: 35958598 [TBL] [Abstract][Full Text] [Related]
9. Based on scRNA-seq and bulk RNA-seq to establish tumor immune microenvironment-associated signature of skin melanoma and predict immunotherapy response. Li S; Zhao J; Wang G; Yao Q; Leng Z; Liu Q; Jiang J; Wang W Arch Dermatol Res; 2024 May; 316(6):262. PubMed ID: 38795156 [TBL] [Abstract][Full Text] [Related]
10. Development of a novel prognostic signature based on single-cell combined bulk RNA analysis in breast cancer. Xiao Y; Hu G; Xie N; Yin L; Pan Y; Liu C; Lou S; Zhu C J Gene Med; 2024 Feb; 26(2):e3673. PubMed ID: 38404059 [TBL] [Abstract][Full Text] [Related]
11. Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. Cui H; Ren X; Dai L; Chang L; Liu D; Zhai Z; Kang H; Ma X Front Immunol; 2023; 14():1145552. PubMed ID: 36969219 [TBL] [Abstract][Full Text] [Related]
12. Establishment of an ovarian cancer omentum metastasis-related prognostic model by integrated analysis of scRNA-seq and bulk RNA-seq. Zhang D; Lu W; Cui S; Mei H; Wu X; Zhuo Z J Ovarian Res; 2022 Nov; 15(1):123. PubMed ID: 36424614 [TBL] [Abstract][Full Text] [Related]
13. PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer. Ren X; Cui H; Dai L; Chang L; Liu D; Yan W; Zhao X; Kang H; Ma X J Cancer Res Clin Oncol; 2024 Mar; 150(3):119. PubMed ID: 38466449 [TBL] [Abstract][Full Text] [Related]
14. Integrating Single-Cell RNA-Seq and Bulk RNA-Seq Data to Explore the Key Role of Fatty Acid Metabolism in Breast Cancer. Chen Y; Wu W; Jin C; Cui J; Diao Y; Wang R; Xu R; Yao Z; Li X Int J Mol Sci; 2023 Aug; 24(17):. PubMed ID: 37686016 [TBL] [Abstract][Full Text] [Related]
15. Integrative transcriptional characterization of cell cycle checkpoint genes promotes clinical management and precision medicine in bladder carcinoma. Shi WW; Guan JZ; Long YP; Song Q; Xiong Q; Qin BY; Ma ZQ; Hu Y; Yang B Front Oncol; 2022; 12():915662. PubMed ID: 36033441 [TBL] [Abstract][Full Text] [Related]
16. A Novel Aging-Related Prognostic lncRNA Signature Correlated with Immune Cell Infiltration and Response to Immunotherapy in Breast Cancer. Liu Z; Ren C; Cai J; Yin B; Yuan J; Ding R; Ming W; Sun Y; Li Y Molecules; 2023 Apr; 28(8):. PubMed ID: 37110517 [TBL] [Abstract][Full Text] [Related]
17. Advanced machine learning unveils CD8 + T cell genetic markers enhancing prognosis and immunotherapy efficacy in breast cancer. Ma H; Shi L; Zheng J; Zeng L; Chen Y; Zhang S; Tang S; Qu Z; Xiong X; Zheng X; Yin Q BMC Cancer; 2024 Oct; 24(1):1222. PubMed ID: 39354417 [TBL] [Abstract][Full Text] [Related]
18. T-cell exhaustion signatures characterize the immune landscape and predict HCC prognosis Chi H; Zhao S; Yang J; Gao X; Peng G; Zhang J; Xie X; Song G; Xu K; Xia Z; Chen S; Zhao J Front Immunol; 2023; 14():1137025. PubMed ID: 37006257 [TBL] [Abstract][Full Text] [Related]
19. scRNA-seq revealed high stemness epithelial malignant cell clusters and prognostic models of lung adenocarcinoma. Lin G; Gao Z; Wu S; Zheng J; Guo X; Zheng X; Chen R Sci Rep; 2024 Feb; 14(1):3709. PubMed ID: 38355636 [TBL] [Abstract][Full Text] [Related]
20. Integrated analysis of single-cell RNA-seq and bulk RNA-seq unravels T cell-related prognostic risk model and tumor immune microenvironment modulation in triple-negative breast cancer. Guo S; Liu X; Zhang J; Huang Z; Ye P; Shi J; Stalin A; Wu C; Lu S; Zhang F; Gao Y; Jin Z; Tao X; Huang J; Zhai Y; Shi R; Guo F; Zhou W; Wu J Comput Biol Med; 2023 Jul; 161():107066. PubMed ID: 37263064 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]